Slobodan Radumilo

Slobodan Radumilo

SVP, President, International

Slobodan Radumilo serves as the SVP, President International for embecta.  Slobodan is also Chair to the Diabetes Sector Group at Med-tech Europe. Prior to this role, Slobodan worked at Medtronic between 1997 and 2016, holding roles of increasing responsibility, most recently as Vice-President of Neuromodulation for Europe and Canada, Regional Vice President for Central and Eastern Europe and Central Asia, and Regional Vice President for Central and Eastern Europe, Greece and Israel. In his regional roles, Slobodan managed all of Medtronic operations in more than 25 countries of the world with population of half a billion. Slobodan had been a member of the Officer Group of Medtronic Inc. since 2011.

Slobodan’s experience has been characterized by his ability to work with governments around the world to improve awareness, access, and affordability of healthcare. Throughout his career, Slobodan has always sought to bring innovation to the center of his business activities and has a passion for developing outstanding talent and forming winning teams.

Slobodan holds a Bachelor of Science degree in Electrical Engineering, a Master of Science degree in Biomedical Engineering and a Diploma in Management from the University of Zagreb (Croatia), as well as a Diploma in Leadership from the Glasgow Caledonian University.

    Forward Looking Statement

    The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, transcripts, newsletters and similar events and communications contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws, based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of embecta may differ materially from those expressed or implied by such forward-looking statements and assumptions.These statements use words such as "will," "plan," "expect," "anticipate," "estimate," "next," "project," "potential," "continue," "expand" and "grow" and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and statements regarding our business strategy, impact of mergers and acquisitions,future product development, regulatory clearances and approvals, competitive position and expenditures.These statements are based on current assumptions and expectations of future events at the time they are made and thus are inherently subject to uncertainty.

    All such statements are based upon current expectations of embecta and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company's control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.